We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
-14.5%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
AUM
$94.3M
AUM Growth
-$19.5M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
8
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$739M
$34.3M 36.39%
1,954,904
NTRA icon
2
Natera
NTRA
$36.4B
$14.5M 15.32%
127,305
XLRN
3
DELISTED
Acceleron Pharma
XLRN
$13.6M 14.45%
108,630
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$8.3M 8.79%
998,278
KYNB
5
Kyntra Bio
KYNB
$28.9M
$8.14M 8.63%
12,231
VRNA
6
DELISTED
Verona Pharma
VRNA
$7.27M 7.7%
1,111,112
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$7.16M 7.59%
1,641,804
NVAX icon
8
Novavax
NVAX
$1.22B
$1.06M 1.13%
5,000

Similar funds

Foresite Capital Management III's Q2 2021 Portfolio in Review

As of Q2 2021, Foresite Capital Management III held 8 positions worth $94.3M, down 17% from $114M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2021: portfolio turnover was 0%. Foresite Capital Management III opened no new positions and made no exits, leaving the 8-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management III's ten largest holdings make up 100% of its $94.3M portfolio in Q2 2021.
  • Foresite Capital Management III opened 0 new positions and closed 0 in Q2 2021.
  • Foresite Capital Management III's portfolio value fell 17% quarter-over-quarter to $94.3M.

Based on Foresite Capital Management III's 13F filing for Q2 2021, filed 16 Aug 2021.